Showing 1 - 3 results of 3 for search 'J. Lancet', query time: 0.02s Refine Results
  1. 1
    P587: COVALENT-101: A PHASE 1 STUDY OF BMF-219, A NOVEL ORAL IRREVERSIBLE MENIN INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, AND MULTIPLE MYELOMA

    P587: COVALENT-101: A PHASE 1 STUDY OF BMF-219, A NOVEL ORAL IRREVERSIBLE MENIN INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, AND M... by F. Ravandi-Kashani, A. Kishtagari, H. Carraway, G. Schiller, E. Curran, B. Yadav, A. Cacovean, S. Morris, T. Butler, J. Lancet

    Published 2022-06-01
    Get full text
    Article
  2. 2
    P755: HYPERFERRITINEMIA IS A PREDICTIVE BIOMARKER OF POOR CLINICAL OUTCOMES IN CMML

    P755: HYPERFERRITINEMIA IS A PREDICTIVE BIOMARKER OF POOR CLINICAL OUTCOMES IN CMML by L. E. Aguirre, S. Ball, A. Jain, N. Al Ali, D. Sallman, A. Kuykendall, K. Sweet, J. Lancet, E. Padron, R. Komrokji

    Published 2022-06-01
    Get full text
    Article
  3. 3
    P1073: MUTATIONAL LANDSCAPE AND CLINICAL OUTCOMES OF PATIENTS WITH MYELOID AND LYMPHOID NEOPLASMS WITH EOSINOPHILIA (MLN-EOS) AND ABNORMALITIES OF PDGFRA, PDGFRB, FGFR1, FLT3 AND JAK REARRANGEMENT

    P1073: MUTATIONAL LANDSCAPE AND CLINICAL OUTCOMES OF PATIENTS WITH MYELOID AND LYMPHOID NEOPLASMS WITH EOSINOPHILIA (MLN-EOS) AND ABNORMALITIES OF PDGFRA, PDGFRB, FGFR1, FLT3 AND J... by Y. Zhang, L. Nguyen, C. Lu, E. Wang, M. Lauw, S. Ball, N. Dong, L. Moscinski, O. Chan, S. Yun, D. Sallman, L. Sokol, B. Shah, J. Lancet, R. Komrokji, A. Kuykendall, E. Padron, L. Zhang

    Published 2022-06-01
    Get full text
    Article

Search Tools: